Live Quote · NASDAQMXCTHealthcare· Biotechnology

MaxCyte, Inc.

$1.22 1.22%($-0.01)
TickerSpark Score
56/100
Mixed
67
Valuation
40
Profitability
10
Growth
84
Health
80
Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MXCT research report →

52-Week Range33% of range
Low
$0.64
Current
$1.22
High
$2.37
Company Overviewwww.maxcyte.com

About the company

MaxCyte, Inc. , a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.

CEO
Maher Masoud
IPO
2021
Employees
91
HQ
Rockville, MD, US

Price Chart

-45.54% · this period
$2.33$1.50$0.68Jul 02Dec 31Jul 02
Valuation
Market Cap
$130.15M
P/E
-3.25
P/S
4.03
P/B
0.77
EV/EBITDA
-3.84
Div Yield
0.00%
Profitability
Gross Margin
80.70%
Op Margin
-119.73%
Net Margin
-121.16%
ROE
-22.03%
ROIC
-20.82%
Growth & Income
Revenue
$33.03M · -14.50%
Net Income
$-44,630,000 · -8.71%
EPS
$-0.42 · -7.69%
Op Income
$-45,285,000
FCF YoY
-23.64%
Performance & Tape
52W High
$2.37
52W Low
$0.64
50D MA
$1.06
200D MA
$1.20
Beta
1.67
Avg Volume
1.14M

Get TickerSpark's AI analysis on MXCT

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

DateInsiderTypeShares
Jun 17, 26Johnston John Josephother30,421
Jun 17, 26Johnston John Josephother49,579
Jun 17, 26Hemrajani Rekhaother30,421
Jun 17, 26Hemrajani Rekhaother49,579
Jun 17, 26Erck Stanley Cother30,421
Jun 17, 26Erck Stanley Cother49,579
Jun 17, 26DOUGLAS RICHARDother30,421
Jun 17, 26DOUGLAS RICHARDother49,579
Jun 17, 26Collins Cynthiaother30,421
Jun 17, 26Collins Cynthiaother49,579
Coverage · MXCT

Our MXCT coverage

Recent articles, reports, and earnings notes.

On-Demand Research

No research on MXCT yet

For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.

Generate MXCT report →
Internal Compare

Similar companies

Peers in the same neighborhood.